Literature DB >> 9010043

CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer.

M Fukuoka1, N Masuda, S Negoro, K Matsui, T Yana, S Kudoh, Y Kusunoki, M Takada, M Kawahara, M Ogawara, N Kodama, K Kubota, K Furuse.   

Abstract

Sixty-three patients with extensive-stage small-cell lung cancer were randomized to receive either cyclophosphamide, vincristine, doxorubicin and etoposide (CODE) alone or CODE plus recombinant human granulocyte colony-stimulating factor (rhG-CSF). rhG-CSF administration in support of CODE chemotherapy resulted in increased mean total received dose intensity for all drugs (P = 0.03) with a significant improvement in survival (P = 0.004).

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9010043      PMCID： PMC2063260          DOI： 10.1038/bjc.1997.50

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  16 in total

1.  Intensive weekly chemotherapy for good-prognosis patients with small-cell lung cancer.

Authors:  D W Miles; H M Earl; R L Souhami; P G Harper; R Rudd; C M Ash; L James; C W Trask; J S Tobias; S G Spiro
Journal:  J Clin Oncol       Date:  1991-02       Impact factor: 44.544

2.  Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: a Southwest Oncology Group pilot study.

Authors:  C W Taylor; J Crowley; S K Williamson; T P Miller; S A Taylor; T G Giri; R L Stephens; R B Livingston
Journal:  J Clin Oncol       Date:  1990-11       Impact factor: 44.544

3.  Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.

Authors:  J Crawford; H Ozer; R Stoller; D Johnson; G Lyman; I Tabbara; M Kris; J Grous; V Picozzi; G Rausch
Journal:  N Engl J Med       Date:  1991-07-18       Impact factor: 91.245

4.  Brief intensive chemotherapy for metastatic non-small-cell lung cancer: a phase II study of the weekly CODE regimen.

Authors:  N Murray; D Osoba; A Shah; R Page; H Karsai; C Little
Journal:  J Natl Cancer Inst       Date:  1991-02-06       Impact factor: 13.506

5.  Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer.

Authors:  N Murray; A Shah; D Osoba; R Page; H Karsai; C Grafton; K Goddard; R Fairey; N Voss
Journal:  J Clin Oncol       Date:  1991-09       Impact factor: 44.544

6.  Role of chemotherapy in small cell lung cancer: a consensus report of the International Association for the Study of Lung Cancer workshop.

Authors:  J Aisner; P Alberto; J Bitran; R Comis; J Daniels; H Hansen; H Ikegami; J Smyth
Journal:  Cancer Treat Rep       Date:  1983-01

7.  A pilot study of intensive weekly chemotherapy for extensive disease small-cell lung carcinoma.

Authors:  G L Wampler; J D Ahlgren; R S Schulof
Journal:  Cancer Invest       Date:  1992       Impact factor: 2.176

8.  Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.

Authors:  P J Woll; J Hodgetts; L Lomax; F Bildet; V Cour-Chabernaud; N Thatcher
Journal:  J Clin Oncol       Date:  1995-03       Impact factor: 44.544

9.  Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.

Authors:  M H Bronchud; J H Scarffe; N Thatcher; D Crowther; L M Souza; N K Alton; N G Testa; T M Dexter
Journal:  Br J Cancer       Date:  1987-12       Impact factor: 7.640

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640
View more
  9 in total

1.  Predictors of response of patients with solid tumors to granulocyte colony-stimulating factor.

Authors:  Hiroaki Ohnaka; Hitoshi Tsukamoto; Toshiaki Nakamura; Ryoichi Yano; Kyohei Watanabe; Toshiaki Igarashi; Nobuyuki Goto; Mikio Masada
Journal:  Int J Clin Pharm       Date:  2012-09-26

Review 2.  Treatment and outcomes for elderly patients with small cell lung cancer.

Authors:  R J Stephens; D H Johnson
Journal:  Drugs Aging       Date:  2000-09       Impact factor: 3.923

3.  Extensive disease small cell lung cancer dose-response relationships: implications for resistance mechanisms.

Authors:  David J Stewart; Constance Johnson; Adriana Lopez; Bonnie Glisson; Jay M Rhee; B Nebiyou Bekele
Journal:  J Thorac Oncol       Date:  2010-11       Impact factor: 15.609

4.  A phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606).

Authors:  H Kunitoh; T Tamura; T Shibata; K Takeda; N Katakami; K Nakagawa; A Yokoyama; Y Nishiwaki; K Noda; K Watanabe; N Saijo
Journal:  Br J Cancer       Date:  2010-06-15       Impact factor: 7.640

Review 5.  Modern management of small-cell lung cancer.

Authors:  Roberta Ferraldeschi; Sofia Baka; Babita Jyoti; Corinne Faivre-Finn; Nick Thatcher; Paul Lorigan
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 6.  Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.

Authors:  Julia Bohlius; Christine Herbst; Marcel Reiser; Guido Schwarzer; Andreas Engert
Journal:  Cochrane Database Syst Rev       Date:  2008-10-08

7.  Small cell lung cancer.

Authors:  Gregory P Kalemkerian; Wallace Akerley; Paul Bogner; Hossein Borghaei; Laura Qm Chow; Robert J Downey; Leena Gandhi; Apar Kishor P Ganti; Ramaswamy Govindan; John C Grecula; James Hayman; Rebecca Suk Heist; Leora Horn; Thierry Jahan; Marianna Koczywas; Billy W Loo; Robert E Merritt; Cesar A Moran; Harvey B Niell; Janis O'Malley; Jyoti D Patel; Neal Ready; Charles M Rudin; Charles C Williams; Kristina Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2013-01-01       Impact factor: 11.908

8.  A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605).

Authors:  H Kunitoh; T Tamura; T Shibata; K Nakagawa; K Takeda; Y Nishiwaki; Y Osaki; K Noda; A Yokoyama; N Saijo
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 7.640

9.  Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507.

Authors:  I Sekine; Y Nishiwaki; R Kakinuma; K Kubota; F Hojo; T Matsumoto; H Ohmatsu; K Goto; T Kodama; K Eguchi; T Shinkai; T Tamura; Y Ohe; H Kunitoh; K Yoshimura; N Saijo
Journal:  Br J Cancer       Date:  2003-03-24       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.